piritrexim
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 1997 (NCT00002914)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Dihydrofolate reductaseINHIBITOR
Dihydrofolate reductase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(OC)c(Cc2cnc3nc(N)nc(N)c3c2C)c1- Mol. weight
- 325.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL7492 ↗
Also known as
- 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine
- bw301u
- bw 301u
- bw-301u
- piritrexim
- piritrexim
- piritrexim
- piritrexim
- piritrexim monohydrochloride
- pyrido(2,3-d)pyrimidine-2,4-diamine, 6-((2,5-dimethoxyphenyl)methyl)-5-methyl-
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002914 | Phase 2 | May 1, 1997 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Vanderbilt University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 1997 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1997 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 1997 |
3 organizations
Page 1 / 1